Cardiovascular revascularization medicine : including molecular interventions
Authors: Kolte D, Butala NM, Kennedy KF, Wasfy JH, Jena AB, Sakhuja R, Langer N, Melnitchouk S, Sundt TM, Passeri JJ, Palacios IF, Inglessis I, Elmariah S
Volume 77 of Issue 6 | American journal of kidney diseases : the official journal of the National Kidney Foundation
Authors: Chen TK, Sperati CJ, Thavarajah S, Grams ME
An estimated 8% to 16% of the world's population has chronic kidney disease, defined by low glomerular filtration rate or albuminuria. Progression of chronic kidney disease is associated with adverse outcomes, including incident kidney failure with replacement therapy, accelerated cardiovascular disease, disability, and mortality. Therefore, slowing kidney function decline is paramount in the management of a patient with chronic kidney disease. Ascertaining the cause of kidney disease is an important first step and may compel specific therapies. Effective approaches that apply to the vast majority of patients with chronic kidney disease include the optimization of blood pressure and blockade of the renin-angiotensin-aldosterone system, particularly if albuminuria is present. Recent studies suggest that sodium/glucose cotransporter 2 inhibitors are highly effective treatments in patients with diabetes and/or albuminuria. For patients with type 2 diabetes, glycemic control is important in preventing the development of microvascular complications, and glucagon-like peptide 1 receptor agonists may help reduce albuminuria levels. Other strategies include correcting metabolic acidosis, maintaining ideal body weight, following diets that are low in sodium and animal protein, and avoiding potential nephrotoxins such as nonsteroidal anti-inflammatories, proton-pump inhibitors, and iodinated contrast.
View on PubMed
Authors: Tovar M, Peinado J, Palomino S, Llanos F, Ramírez C, Valderrama G, Calderón RI, Williams RB, Velásquez GE, Mitnick CD, Franke MF, Lecca L
Authors: Chen EH, Losak MJ, Hernandez A, Addo N, Huen W, Mercer MP
Authors: Shmidt E, Ho EY, Feuerstein JD, Singh S, Terdiman JP
Drug and alcohol dependence
Authors: Watkins SL, Karliner-Li P, Lee YO, Koester KA, Ling PM
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
Authors: Sharma P, Sui Z, Zhang M, Magee JC, Barman P, Patel Y, Schluger A, Walter K, Biggins SW, Cullaro G, Wong R, Lai JC, Jo J, Sinha J, VanWagner L, Verna EC
Neuro-oncology
Authors: Tawbi HA, Forsyth PA, Hodi FS, Lao CD, Moschos SJ, Hamid O, Atkins MB, Lewis K, Thomas RP, Glaspy JA, Jang S, Algazi AP, Khushalani NI, Postow MA, Pavlick AC, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Tarhini AA, Sumbul A, Rizzo JI, Margolin KA
Genome medicine
Authors: Kasela S, Ortega VE, Martorella M, Garudadri S, Nguyen J, Ampleford E, Pasanen A, Nerella S, Buschur KL, Barjaktarevic IZ, Barr RG, Bleecker ER, Bowler RP, Comellas AP, Cooper CB, Couper DJ, Criner GJ, Curtis JL, Han MK, Hansel NN, Hoffman EA, Kaner RJ, Krishnan JA, Martinez FJ, McDonald MN, Meyers DA, Paine R, Peters SP, Castro M, Denlinger LC, Erzurum SC, Fahy JV, Israel E, Jarjour NN, Levy BD, Li X, Moore WC, Wenzel SE, Zein J, NHLBI SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) , NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium , Langelier C, Woodruff PG, Lappalainen T, Christenson SA
Science advances
Authors: Lee Y, Bogdanoff D, Wang Y, Hartoularos GC, Woo JM, Mowery CT, Nisonoff HM, Lee DS, Sun Y, Lee J, Mehdizadeh S, Cantlon J, Shifrut E, Ngyuen DN, Roth TL, Song YS, Marson A, Chow ED, Ye CJ
